Table 1b.
Strategic objective indicators and targets (as established in 2013).
| Strategic objective | Indicator | Target |
|---|---|---|
| 1 All countries commit to immunization as a priority | 1.1. Domestic expenditures for immunization per person targeted | Increasing trend |
| 1.2. Presence of an independent technical advisory group that meets defined criteria | Functional groups in all countries | |
| 2 Individuals and communities understand the value of vaccines and demand immunization both as a right and a responsibility | 2.1. Percentage of countries that have assessed (or measured) the level of confidence in vaccination at subnational level** | Increasing trend |
| 2.2. Percentage of un- and under-vaccinated in whom lack of confidence was a factor that influenced their decision** | Decreasing trend | |
| 3 The benefits of immunization are equitably extended to all people | 3.1. Percentage of districts with 80% or greater coverage with three doses of diphtheria-tetanus-pertussis containing vaccine | 2020: all districts in all countries |
| 3.2. Reduction in coverage gaps between wealth quintiles and other appropriate equity indicator(s) | Increasing trend in equity | |
| 4 Strong immunization systems are an integral part of a well-functioning health system | 4.1. Dropout rate between first dose (DTP1) and third dose (DTP3) of diphtheria-tetanus-pertussis-containing vaccines | Decreasing trend |
| 4.2. Sustained coverage of diptheria-tetanus-pertussis-containing vaccines 90% or greater for three or more years | 2020: all countries | |
| 4.3. Immunization coverage data assessed as high quality by WHO and UNICEF | 2020: all countries | |
| 4.4. Number of countries with case-based surveillance for vaccine-preventable diseases | 2015: all countriesfor polio and measles 2020: 75% of LMICs for sentinel site surveillance |
|
| 5 Immunization programmes have sustainable access to predictable funding, quality supply and innovative technologies | 5.1. Percentage of doses of vaccine used worldwide that are of assured quality | 2020: 100% of all vaccine doses |
| 6 Country, regional and global research and development innovations maximize the benefits of immunization | 6.1. Progress towards development of HIV, TB, and malaria vaccines | Proof of concept for a vaccine with ≥ 75% efficacy |
| 6.2. Progress towards a universal influenza vaccine (protecting against drift and shift variants) | At least one vaccine licensed | |
| 6.3. Progress towards institutional and technical capacity carry out vaccine clinical trials | Every region with solid base | |
| 6.4. Number of vaccines that have either been re-licensed or licensed for use in a controlled-temperature chain at temperatures above the traditional 2–8 °C range | Increasing number | |
| 6.5. Number of vaccine delivery technologies (devices and equipment) that have received WHO prequalification against the 2010 baseline | Increasing number |
**
Provisional indicator to be finalized based on outcomes of pilot assessment in selected regions.